Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
piclidenoson · 3 trials · 4 indications
Improvement of psoriasis by 75% or more
Improvement of psoriasis by physicians' judgment
All adverse events occurring the trial will be recorded
The primary end-point is to assess whether treatment for 6 months with piclidenoson improves the functioning of renal proximal tubular cells (PTCs), as assessed by the increase in 99mTc-DMSA uptake as compared to Baseline
Proportion of subjects alive and free of respiratory failure (defined as need for non-invasive or invasive mechanical ventilation, high-flow oxygen, or extracorporeal membrane oxygenation) at Day 29
Proportion of subjects alive and discharged to home without need for supplemental oxygen at Day 29
Proportion of patients experiencing AEs
| Arm | Type | Description |
|---|---|---|
| Piclidenoson treatment | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Piclidenoson (CF101) open-label treated patients | EXPERIMENTAL | Piclidenoson will be administered orally at a dose of 3 mg twice per day for 6 months |
| Piclidenoson | EXPERIMENTAL | Piclidenoson 2 mg every 12 hours orally added to standard of care |
| Name | Type | Description |
|---|---|---|
| piclidenoson | DRUG | Piclidenoson is a selective A3AR agonist, supplied as tablets. |
| Placebo | DRUG | Inactive control |
Inclusion Criteria: 1. Male or female, 18 years and above; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement ≥10%; 3. PASI score ≥12 at the Screening and Baseline visits; 4. Static PGA ≥3 at the Screening and Baseline visits; 5. Candidate for systemic treatment o...
Piclidenoson is an investigational small molecule being studied for the treatment of Lowe Syndrome, plaque psoriasis, and COVID-19. It is being developed by Can-Fite Biopharma Ltd (CANF). The drug is currently in clinical trials, including a Phase 3 study for moderate-to-severe plaque psoriasis and Phase 2 studies for Lowe Syndrome and COVID-19.
Piclidenoson targets the ADORA3 receptor, acting as an agonist. This means it binds to and activates the adenosine A3 receptor. The drug is being investigated for its potential effects in conditions such as plaque psoriasis, Lowe Syndrome, and COVID-19, though its exact mechanism in these diseases is still under study.
Piclidenoson is being developed by Can-Fite Biopharma Ltd, a biopharmaceutical company traded under the ticker symbol CANF. The company is conducting clinical trials for the drug across multiple indications, including plaque psoriasis, Lowe Syndrome, and COVID-19.
Piclidenoson is in Phase 2 and Phase 3 clinical development. It has a completed Phase 2 trial for COVID-19, a Phase 2 trial for Lowe Syndrome that has not yet started recruiting, and a Phase 3 trial for plaque psoriasis that is also not yet recruiting. The drug is investigational and not yet approved.
Piclidenoson has three registered clinical trials. NCT04333472 is a completed Phase 2 study for COVID-19 with 6 participants. NCT06643260 is a planned Phase 3 study for moderate-to-severe plaque psoriasis with 705 participants. NCT07410455 is a planned Phase 2 pilot study for Lowe Syndrome with 5 participants.
Piclidenoson is also known by the code name CF101. The drug is being developed by Can-Fite Biopharma for multiple indications, including plaque psoriasis, Lowe Syndrome, and COVID-19. It is an adenosine A3 receptor agonist currently in clinical trials.